Bortezomib enhances the efficacy of fulvestrant by amplifying the aggregation of the estrogen receptor, which leads to a proapoptotic unfolded protein response

Clinical Cancer Research

Volumn 17, Issue 8, 2011, Pages 2292-2300

  Ishii, Yuki ^a   Papa, Luena ^a   Bahadur, Urvashi ^a   Yue, Zhenyu ^b   Aguirre Ghiso, Julio ^a   Shioda, Toshi ^c   Waxman, Samuel ^a   Germain, Doris ^a,b  

^a Tisch Cancer Institute   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CYCLIN D1; ESTROGEN RECEPTOR; FULVESTRANT; TAMOXIFEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER REGRESSION; CANCER RESISTANCE; CELL METABOLISM; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; HUMAN CELL; METABOLIC RATE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROAPOPTOTIC UNFOLDED PROTEIN RESPONSE; PROTEIN AGGREGATION; PROTEIN DEFECT; PROTEIN DEGRADATION; PROTEIN FOLDING; PROTEIN LOCALIZATION; TREATMENT RESPONSE;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; BORONIC ACIDS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL NUCLEUS; CYTOPLASM; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ESTRADIOL; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GREEN FLUORESCENT PROTEINS; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; PYRAZINES; RECEPTORS, ESTROGEN; TAMOXIFEN; TUMOR BURDEN; UNFOLDED PROTEIN RESPONSE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79954572536     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-1745     Document Type: Article

References (27)

1. Buzdar AU, Robertson JF. Fulvestrant: pharmacologic profile versus existing endocrine agents for the treatment of breast cancer. Ann Pharmacother 2006;40:1572-83. (Pubitemid 44330201)
2. Stenoien DL, Patel K, Mancini MG, Dutertre M, Smith CL, O'Malley BW, et al. FRAP reveals that mobility of oestrogen receptor-alpha is ligand-and proteasome-dependent. Nat Cell Biol 2001;3:15-23. (Pubitemid 32114827)
3. Dauvois S, White R, Parker MG. The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J Cell Sci 1993;106:1377-88. (Pubitemid 24018422)
4. Htun H, Holth LT, Walker D, Davie JR, Hager GL. Direct visualization of the human estrogen receptor alpha reveals a role for ligand in the nuclear distribution of the receptor. Mol Biol Cell 1999;10:471-86. (Pubitemid 29156485)
5. Pick H, Jankevics H, Vogel H. Distribution plasticity of the human estrogen receptor alpha in live cells: distinct imaging of consecutively expressed receptors. J Mol Biol 2007;374:1213-23. (Pubitemid 350122544)
6. Ding WX, Yin XM. Sorting, recognition and activation of the misfolded protein degradation pathways through macroautophagy and the proteasome. Autophagy 2008;4:141-50.
7. Schroder M. Endoplasmic reticulum stress responses. Cell Mol Life Sci 2008;65:862-94.
8. Nishitoh H, Matsuzawa A, Tobiume K, Saegusa K, Takeda K, Inoue K, et al. ASK1 is essential for endoplasmic reticulum stress-induced neuronal cell death triggered by expanded polyglutamine repeats. Genes Dev 2002;16:1345-55. (Pubitemid 34615088)
9. Nishitoh H, Saitoh M, Mochida Y, Takeda K, Nakano H, Rothe M, et al. ASK1 is essential for JNK/SAPK activation by TRAF2. Mol Cell 1998;2:389-95. (Pubitemid 128379279)
10. Davies MP, Barraclough DL, Stewart C, Joyce KA, Eccles RM, Barraclough R, et al. Expression and splicing of the unfolded protein response gene XBP-1 are significantly associated with clinical outcome of endocrine-treated breast cancer. Int J Cancer 2008;123:85-8. (Pubitemid 351705195)
11. Gu Z, Lee RY, Skaar TC, Bouker KB, Welch JN, Lu J, et al. Association of interferon regulatory factor-1, nucleophosmin, nuclear factor-kappaB, and cyclic AMP response element binding with acquired resistance to Faslodex (ICI 182, 780). Cancer Res 2002;62:3428-37. (Pubitemid 34651389)
12. Bross PF, Kane R, Farrell AT, Abraham S, Benson K, Brower ME, et al. Approval summary for bortezomib for injection in the treatment of multiple myeloma. Clin Cancer Res 2004;10:3954-64. (Pubitemid 38812468)
13. Landowski TH, Megli CJ, Nullmeyer KD, Lynch RM, Dorr RT. Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines. Cancer Res 2005;65:3828-36. (Pubitemid 40616363)
14. Ishii Y, Waxman S, Germain D. Tamoxifen stimulates the growth of cyclin D1-overexpressing breast cancer cells by promoting the activation of signal transducer and activator of transcription 3. Cancer Res 2008;68:852-60. (Pubitemid 351206763)
15. Callige M, Kieffer I, Richard-Foy H. CSN5/Jab1 is involved in ligand dependent degradation of estrogen receptor {alpha} by the proteasome. Mol Cell Biol 2005;25:4349-58. (Pubitemid 40705742)
16. Callige M, Richard-Foy H. Ligand-induced estrogen receptor alpha degradation by the proteasome: new actors? Nucl Recept Signal 2006;4:e004.
17. Milani M, Rzymski T, Mellor HR, Pike L, Bottini A, Generali D, et al. The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with Bortezomib. Cancer Res 2009;69:4415-23.
18. Coser KR, Wittner BS, Rosenthal NF, Collins SC, Melas A, Smith SL, et al. Antiestrogen-resistant subclones of MCF-7 human breast cancer cells are derived from a common monoclonal drug-resistant progenitor. Proc Natl Acad Sci U S A 2009;106:14536-41.
19. Herynk MH, Fuqua SA. Estrogen receptor mutations in human disease. Endocr Rev 2004;25:869-98. (Pubitemid 39657771)
20. Gomez BP, Riggins RB, Shajahan AN, Klimach U, Wang A, Crawford AC, et al. Human X-box binding protein-1 confers both estrogen independence and antiestrogen resistance in breast cancer cell lines. FASEB J 2007;21:4013-27. (Pubitemid 350232358)
21. Pratt MA, Bishop TE, White D, Yasvinski G, Menard M, Niu MY, et al. Estrogen withdrawal-induced NF-kappaB activity and bcl-3 expression in breast cancer cells: roles in growth and hormone independence. Mol Cell Biol 2003;23:6887-900. (Pubitemid 37220039)
22. Riggins RB, Zwart A, Nehra R, Clarke R. The nuclear factor kappa B inhibitor parthenolide restores ICI 182, 780 (Faslodex; fulvestrant) - induced apoptosis in antiestrogen-resistant breast cancer cells. Mol Cancer Ther 2005;4:33-41. (Pubitemid 40268064)
23. McConkey DJ, Zhu K. Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist Updat 2008;11:164-79.
24. Lee AH, Iwakoshi NN, Anderson KC, Glimcher LH. Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc Natl Acad Sci U S A 2003;100:9946-51. (Pubitemid 37087048)
25. Clarke R, Shajahan AN, Riggins RB, Cho Y, Crawford A, Xuan J, et al. Gene network signaling in hormone responsiveness modifies apoptosis and autophagy in breast cancer cells. J Steroid Biochem Mol Biol 2009;114:8-20.
26. Zhu K, Dunner K. Jr, McConkey DJ. Proteasome inhibitors activate autophagy as a cytoprotective response in human prostate cancer cells. Oncogene 2009;29:451-62.
27. Powers GL, Ellison-Zelski SJ, Casa AJ, Lee AV, Alarid ET. Proteasome inhibition represses ERalpha gene expression in ER+ cells: a new link between proteasome activity and estrogen signaling in breast cancer. Oncogene. 2009;29:1509-18.